Exemestane

Class:
Antineoplastic Agent, Aromatase Inactivator

Indications:
Breast cancer

Available dosage form in the hospital:
25 mg TAB

Trade Names:
Aromasin

Doses:
Females: Postmenopausal:
-Breast cancer, advanced: Oral: 25 mg once daily; continue until tumor progression
-Breast cancer, early (adjuvant treatment): Oral: 25 mg once daily (following 2-3 years of tamoxifen therapy) for a total duration of 5 years of endocrine therapy (in the absence of recurrence or contralateral breast cancer)
-Breast cancer, risk reduction (unlabeled use): Oral: 25 mg once daily for up to 5 years (Goss, 2011)
-Dosage adjustment with CYP3A4 inducers: U.S. labeling: 50 mg once daily when used with potent inducers (eg, rifampin, phenytoin).

Geriatric : Refer to adult dosing

Renal Impairment: No adjustment necessary (although the safety of chronic doses in patients with moderate-to-severe renal impairment has not been studied, dosage adjustment does not appear necessary).

Hepatic Impairment: No adjustment necessary (although the safety of chronic doses in patients with moderate-to-severe hepatic impairment has not been studied, dosage adjustment does not appear necessary).

Common side effect:

Cardiovascular: Hypertension (5% to 15%), Edema (6% to 7%); cardiac ischemic events (2%: MI, angina, myocardial ischemia); chest pain

Central nervous system: Fatigue (8% to 22%), insomnia (11% to 14%), pain (13%), headache (7% to 13%), depression (6% to 13%), Dizziness (8% to 10%), anxiety (4% to 10%), fever (5%), confusion, hypoesthesia.

Dermatological: Hyperhidrosis (4% to 18%), alopecia (15%)

Endocrine & metabolic: Hot flashes (13% to 33%)

Gastrointestinal: Nausea (9% to 18%), abdominal pain (6% to 11%), Diarrhea (4% to 10%), vomiting (7%), anorexia (6%), constipation (5%), appetite increased (3%), dyspepsia

Hepatic: Alkaline phosphatase increased (14% to 15%)

Neuromuscular & skeletal: Arthralgia

Pregnancy Risk Factor: X